ArticleFrontiers in immunology2026
Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pediatric-onset multiple sclerosis (POMS) poses unique therapeutic challenges due to high inflammatory activity, early cognitive and psychosocial impact, and difficulties with long-term treatment adherence. This retrospective cohort study evaluated the real-world safety and clinical outcomes of cladribine tablets compared with standard disease-modifying therapies (DMTs) in children and adolescents with POMS. Methods: A retrospective cohort of 47 POMS patients followed at two tertiary neuroimmunology centers was included: 31 received cladribine and 16 other DMTs. Inclusion required at least two years of continuous therapy and annual MRI monitoring. The control group comprised patients who remained on standard DMTs due to stable or well-tolerated disease, while exclusion criteria included prior use of high-potency biological therapies, specifically natalizumab or anti-CD20 agents. Clinical and radiological outcomes were analyzed using standard statistical tests and mixed-effects models. Results: Mean age at onset was 15.1 ± 2.5 years in the cladribine group and 13.8 ± 2.2 years in controls. Baseline disease duration was longer among cladribine-treated patients (3.8 ± 3.4 vs. 2.3 ± 1.8 years). NEDA rates were comparable between groups at Year 1. Relapse rates evolved differently over time (Group × Year interaction p = 0.028), reflecting differences in longitudinal patterns rather than a direct comparison of treatment efficacy. MRI and OCT measures showed no significant differences between groups. Withdrawal rates were lower with cladribine (9.4% vs. 52.6%), and no severe adverse events occurred. Conclusion: Cladribine demonstrated favorable safety, high adherence and comparable outcomes to standard DMTs, supporting its feasibility as an off-label option for selected pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.